Saturday, October 31, 2026

AI Credit Models Drive 7M Client Surge at Fintech Banks—But Delinquency Risk Looms

Digital banks using AI underwriting added millions of customers in 2025, with Inter & Co onboarding 7 million new clients and Nu Holdings deploying its nuFormer model across 100+ products. Regulatory shifts in Brazil slowed Nu's portfolio growth from 14% to 10%, while Inter projects private payroll loan delinquency above 10% in 2026, exposing model risk concentrated in algorithm-driven lending.

AI Credit Models Drive 7M Client Surge at Fintech Banks—But Delinquency Risk Looms
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Inter & Co welcomed 7 million new clients in 2025, its best annual performance, while Nu Holdings deployed its nuFormer AI credit model to production and launched more than 100 products and features. The customer acquisition surge marks a shift in emerging market lending, where digital banks using machine learning underwriting now outpace traditional competitors.

Nu's newer customer cohorts transact faster than older groups, a pattern Inter also reported. The acceleration reflects AI models identifying creditworthy borrowers traditional banks miss—or mispricing risk that surfaces later.

Brazil's November 2025 FGTS regulation changes triggered the first stress test. Nu's portfolio growth rate dropped from an expected 13-14% to roughly 10% as the AI model struggled to adapt to new lending constraints. The company typically sees 15-90 day NPLs tick up in Q1, indicating sensitivity to external shocks.

Inter expects its cost of risk in 2026 to reach 5.5-6%, with private payroll loan delinquency converging above 10%. The forecast suggests AI-driven growth creates concentrated exposure: models trained on stable periods may misread creditworthiness when macro conditions or regulations shift.

Traditional banks spread underwriting across human judgment and algorithmic inputs, diluting single-model failures. AI-native lenders face binary risk: their models either capture growth opportunities competitors miss or accumulate portfolios that deteriorate together under stress.

Nu's nuFormer deployment shows the upside—rapid feature rollout and customer scaling impossible with manual credit review. Inter's 7 million new clients demonstrate market demand for instant approvals. Both banks rely on algorithms to segment risk across millions of micro-decisions daily.

The delinquency projections reveal the downside. When external variables change—regulation, employment rates, government lending programs—AI models trained on historical patterns may continue approving profiles that no longer perform. Human underwriters adjust heuristics intuitively; algorithms require retraining cycles that lag market shifts.

Emerging market fintech growth now depends on model resilience, not just model accuracy. Banks that built portfolios in 2024-2025's favorable conditions will test whether their AI can navigate 2026's headwinds—or if speed-to-market came at the cost of durability.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com